Most Adults Over 50 Would Consider Dementia Vaccine

A USC survey found 72% of adults 50 and older would likely or definitely get a hypothetical dementia shot, though none is yet available.

Updated on Nov. 8, 2026 in Alzheimer’s

Most Adults Over 50 Would Consider Dementia Vaccine

Live Poll

Would you get a vaccine that cut your dementia risk by half?

A USC Schaeffer Center study of more than 1,500 adults aged 50 or older found that most would consider a hypothetical dementia vaccine, with 72% saying they would likely or definitely get it. The study was published in JAMA Network Open, and no dementia vaccine is currently on the market.

Why it matters

Several dementia vaccine candidates are in clinical trials, so public willingness to accept such a shot could shape how quickly any eventual product reaches people who need it. The survey gives early insight into which groups may be more or less ready to take up a preventive dementia treatment.

This is a survey of more than 1,500 adults aged 50 or older, published in JAMA Network Open, that asked about a hypothetical low-cost, multi-dose vaccine. Because it measured stated intentions for an imaginary product, the results reflect interest rather than actual uptake, and the gaps between age, sex, and racial groups are notable.

The players

USC Schaeffer Center for Health Policy & Economics

The University of Southern California research center that conducted the study on public interest in a dementia vaccine.

The details

Participants rated their interest in a hypothetical vaccine series that would cut dementia risk by half for people at high risk. Several candidate dementia vaccines now in development are immunotherapies designed to train the immune system to clear toxic proteins linked to Alzheimer's disease and other dementias. Willingness to get the shot varied across groups, with women and Black adults less likely to say they would definitely get it.

Timeline

  1. The study article was published on November 8, 2026.

Health Landscape

Dementia vaccine candidates are immunotherapies aimed at clearing toxic proteins linked to Alzheimer's disease, and they remain in clinical trials with no product approved. This survey adds a population-level view of how receptive older U.S. adults may be if such a preventive option becomes available.

If you are over 50, this study suggests a preventive dementia vaccine may draw broad interest once one is available, so it is worth asking your doctor about dementia risk factors and brain health now. Because no such vaccine is on the market yet, keep current on your cognitive health with your physician rather than waiting for a new product.

The takeaway

Most surveyed adults said they would consider a dementia vaccine, but interest varied by sex and race and no product exists yet. Keep up conversations with your doctor about brain health and watch for results from ongoing vaccine trials.

Further reading

For more background on the condition, see our Alzheimer's coverage.

Source note: This article includes information reported by West Newsmagazine.

Live Poll

Would you get a vaccine that cut your dementia risk by half?